Glaukos Q3 revenue $96.7M (+24% YoY), raises 2024 guidance to $377-379M

GLAUKOS Corp

2024-Q3 EPS reported -$2.18 revenue$277,982,000

Record Q3 net sales of $96.7M (+24% YoY); glaucoma segment $76.0M (+30%), corneal health $20.6M (+5%).
GAAP net loss narrowed to $21.4M ($0.39 loss per share) from $30.4M ($0.63) in Q3 2023.
Non-GAAP net loss $15.2M ($0.28 per share) vs $24.2M ($0.50) prior year.
Raised FY2024 net sales guidance to $377M-$379M from prior $370M-$376M.
Gross margin ~77%, non-GAAP ~82%; ended quarter with $267.2M cash.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.